Positive results from a feasibility study investigating Hexvix® with flexible cystoscopy in the outpatient (office) setting have been published in Research and Reports in Urology https://bit.ly/2NBgyez . The investigators concluded that routine outpatient management of patients with Blue Light Cystoscopy (BLC™) with a flexible scope for early identification of recurrent lesions using on-site biopsy, is feasible in patients with non-muscle invasive bladder cancer (NMIBC). As a result, small tumors can be managed immediately with fulguration, avoiding the need for referral to the operating room for rigid cystoscopy and TURB under general anesthesia. Logistically, little training appears to be required for urologists and nurses, and, once healthcare professionals become familiar with the procedure, patient flow is smooth. Therefore, BLC with Hexvix using flexible scopes in the outpatient setting offers potential clinical, economic, and patient benefits in the follow-up of patients with NMIBC.